| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Anne-Lise Børresen-Dale | Q11958220 |
| Anita Langerød | Q65594287 | ||
| Laxmi Silwal-Pandit | Q41608095 | ||
| P2860 | cites work | Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway | Q24302433 |
| International network of cancer genome projects | Q24611474 | ||
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| Mutational processes molding the genomes of 21 breast cancers | Q24620915 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development | Q24631164 | ||
| A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma | Q71079779 | ||
| Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients | Q71169983 | ||
| Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome | Q73748200 | ||
| Mutant p53 gain of function is interwoven into the hallmarks of cancer | Q82183156 | ||
| Links between mutant p53 and genomic instability | Q26864033 | ||
| The changing view of high-grade serous ovarian cancer | Q27025411 | ||
| The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer | Q27824864 | ||
| p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. | Q27851827 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| The landscape of cancer genes and mutational processes in breast cancer | Q29614637 | ||
| The life history of 21 breast cancers | Q29614642 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
| Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome | Q33359495 | ||
| TP53 mutations in human cancers: origins, consequences, and clinical use | Q33685392 | ||
| Mutant p53 gain-of-function in cancer | Q33687048 | ||
| Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel | Q33893910 | ||
| Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Q34103978 | ||
| Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin | Q34123261 | ||
| The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. | Q34125898 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Q34292432 | ||
| p53 Research: the past thirty years and the next thirty years. | Q34313764 | ||
| Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer | Q34736974 | ||
| TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | Q34775855 | ||
| Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma | Q34965421 | ||
| Emerging landscape of oncogenic signatures across human cancers | Q35058708 | ||
| TP53 and ovarian cancer | Q35078757 | ||
| TP53 and breast cancer | Q35078761 | ||
| Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity | Q35079683 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| New concepts in breast cancer genomics and genetics | Q35258057 | ||
| Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers | Q35583968 | ||
| A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. | Q35889414 | ||
| TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer | Q35906287 | ||
| TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer | Q35961836 | ||
| Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth | Q36056465 | ||
| Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival | Q36070080 | ||
| Mutant p53: one name, many proteins | Q36070574 | ||
| N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents | Q36137812 | ||
| Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer | Q36245541 | ||
| Estrogen receptor prevents p53-dependent apoptosis in breast cancer | Q36397942 | ||
| The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer | Q36785983 | ||
| Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers | Q36896061 | ||
| Punctuated evolution of prostate cancer genomes | Q36950514 | ||
| The consequence of oncomorphic TP53 mutations in ovarian cancer | Q37225303 | ||
| APOBEC3B is an enzymatic source of mutation in breast cancer. | Q37533713 | ||
| When mutants gain new powers: news from the mutant p53 field. | Q37582777 | ||
| p53-based cancer therapy | Q37750115 | ||
| Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers | Q38087850 | ||
| p53 in breast cancer subtypes and new insights into response to chemotherapy | Q38145813 | ||
| BRCAness: a deeper insight into basal-like breast tumors | Q38153181 | ||
| TP53 mutations in human cancer: database reassessment and prospects for the next decade | Q38199075 | ||
| Unravelling mechanisms of p53-mediated tumour suppression | Q38205099 | ||
| Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature | Q39377518 | ||
| Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis | Q40694250 | ||
| Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo | Q40907746 | ||
| Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. | Q41046980 | ||
| Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution | Q41130119 | ||
| Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens | Q41905883 | ||
| TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance | Q42458495 | ||
| The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma | Q44103449 | ||
| TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer | Q44679253 | ||
| p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. | Q46219717 | ||
| Whole-genome characterization of chemoresistant ovarian cancer. | Q50272478 | ||
| High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. | Q51742087 | ||
| Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. | Q52193951 | ||
| Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. | Q53337533 | ||
| Molecular Subtypes of High-Grade Serous Ovarian Cancer: The Holy Grail? | Q57255835 | ||
| p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma | Q60936553 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P577 | publication date | 2016-11-04 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | TP53 Mutations in Breast and Ovarian Cancer | |
| P478 | volume | 7 |
| Q92481531 | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers |
| Q64073747 | Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis |
| Q64242607 | Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma |
| Q89919945 | Deciphering the Mounting Complexity of the p53 Regulatory Network in Correlation to Long Non-Coding RNAs (lncRNAs) in Ovarian Cancer |
| Q92503916 | Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis |
| Q89862519 | Genomic Signature of the Standardized Uptake Value in 18F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer |
| Q64987440 | High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer. |
| Q58587067 | Human Disease Ontology 2018 update: classification, content and workflow expansion |
| Q55259197 | Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). |
| Q92922862 | Metabolism of Estrogens: Turnover Differs Between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells |
| Q58744379 | Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients |
| Q58792318 | Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity |
| Q37596828 | The fate of BRCA1-related germline mutations in triple-negative breast tumors |
Search more.